Alaska Permanent Fund Corp Acquires 58 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Alaska Permanent Fund Corp increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,904 shares of the biopharmaceutical company’s stock after purchasing an additional 58 shares during the quarter. Alaska Permanent Fund Corp’s holdings in Regeneron Pharmaceuticals were worth $3,758,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the business. Woodstock Corp boosted its holdings in Regeneron Pharmaceuticals by 4.2% in the first quarter. Woodstock Corp now owns 4,222 shares of the biopharmaceutical company’s stock worth $4,064,000 after purchasing an additional 170 shares during the last quarter. Massmutual Trust Co. FSB ADV boosted its stake in shares of Regeneron Pharmaceuticals by 1.3% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 4,065 shares of the biopharmaceutical company’s stock worth $3,913,000 after buying an additional 52 shares during the last quarter. Rise Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 244.0% in the 1st quarter. Rise Advisors LLC now owns 86 shares of the biopharmaceutical company’s stock worth $83,000 after buying an additional 61 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Regeneron Pharmaceuticals by 21.1% in the first quarter. GAMMA Investing LLC now owns 884 shares of the biopharmaceutical company’s stock worth $851,000 after acquiring an additional 154 shares during the period. Finally, Kapitalo Investimentos Ltda lifted its holdings in Regeneron Pharmaceuticals by 118.2% in the fourth quarter. Kapitalo Investimentos Ltda now owns 240 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 130 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $1,044.39 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. Regeneron Pharmaceuticals, Inc. has a 1-year low of $684.80 and a 1-year high of $1,052.34. The business has a 50 day simple moving average of $964.87 and a two-hundred day simple moving average of $941.08. The stock has a market capitalization of $115.08 billion, a PE ratio of 30.85, a P/E/G ratio of 2.15 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The business had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. UBS Group upped their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research report on Wednesday, April 17th. Royal Bank of Canada raised their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,229.00 and gave the stock an “outperform” rating in a report on Wednesday, June 12th. Bank of America boosted their price target on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a report on Friday, April 12th. JPMorgan Chase & Co. raised their price objective on Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research note on Monday. Finally, Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research note on Wednesday, March 13th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $998.09.

Insiders Place Their Bets

In related news, CEO Leonard S. Schleifer sold 22,830 shares of the stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $979.23, for a total value of $22,355,820.90. Following the completion of the transaction, the chief executive officer now owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director Michael S. Brown sold 1,535 shares of the stock in a transaction on Friday, June 14th. The shares were sold at an average price of $1,040.00, for a total value of $1,596,400.00. Following the sale, the director now owns 1,382 shares of the company’s stock, valued at $1,437,280. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Leonard S. Schleifer sold 22,830 shares of the firm’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the completion of the sale, the chief executive officer now owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The disclosure for this sale can be found here. Insiders sold 61,215 shares of company stock valued at $60,414,782 in the last three months. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.